No Data
No Data
Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'
Design Therapeutics Announces Data From Phase 1 SAD/MAD Trial of DT-168
Design Therapeutics Releases Phase 1 Data For DT-168 Supporting Advancement Into Phase 2 Biomarker Trial For Patients With Fuchs Endothelial Corneal Dystrophy
Express News | Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement Into Phase 2 Biomarker Trial for Patients With Fuchs Endothelial Corneal Dystrophy
Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park City 2025 On May 2, 2025
Press Release: Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer